Cognition Therapeutics Stock Market Value
| CGTX Stock | USD 0.72 0.05 6.49% |
| Symbol | Cognition |
Cognition Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cognition Therapeutics. If investors know Cognition will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cognition Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cognition Therapeutics is measured differently than its book value, which is the value of Cognition that is recorded on the company's balance sheet. Investors also form their own opinion of Cognition Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cognition Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cognition Therapeutics' market value can be influenced by many factors that don't directly affect Cognition Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cognition Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cognition Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cognition Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cognition Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cognition Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cognition Therapeutics.
| 01/02/2025 |
| 02/01/2025 |
If you would invest 0.00 in Cognition Therapeutics on January 2, 2025 and sell it all today you would earn a total of 0.00 from holding Cognition Therapeutics or generate 0.0% return on investment in Cognition Therapeutics over 30 days. Cognition Therapeutics is related to or competes with Reviva Pharmaceuticals, Transcode Therapeutics, Kodiak Sciences, Tscan Therapeutics, Cue Biopharma, Dermata Therapeutics, and Gain Therapeutics. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of sm... More
Cognition Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cognition Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cognition Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.8 | |||
| Information Ratio | 0.0754 | |||
| Maximum Drawdown | 39.6 | |||
| Value At Risk | (9.80) | |||
| Potential Upside | 13.95 |
Cognition Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cognition Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cognition Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cognition Therapeutics historical prices to predict the future Cognition Therapeutics' volatility.| Risk Adjusted Performance | 0.0812 | |||
| Jensen Alpha | 0.5458 | |||
| Total Risk Alpha | 0.022 | |||
| Sortino Ratio | 0.0943 | |||
| Treynor Ratio | 0.6063 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cognition Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cognition Therapeutics Backtested Returns
Cognition Therapeutics appears to be out of control, given 3 months investment horizon. Cognition Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. By analyzing Cognition Therapeutics' technical indicators, you can evaluate if the expected return of 0.94% is justified by implied risk. Please makes use of Cognition Therapeutics' Risk Adjusted Performance of 0.0812, downside deviation of 5.8, and Mean Deviation of 5.26 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cognition Therapeutics holds a performance score of 10. The firm shows a Beta (market volatility) of 1.02, which signifies a somewhat significant risk relative to the market. Cognition Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Cognition Therapeutics is expected to follow. Please check Cognition Therapeutics' total risk alpha and the relationship between the downside variance and period momentum indicator , to make a quick decision on whether Cognition Therapeutics' price patterns will revert.
Auto-correlation | 0.51 |
Modest predictability
Cognition Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Cognition Therapeutics time series from 2nd of January 2025 to 17th of January 2025 and 17th of January 2025 to 1st of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cognition Therapeutics price movement. The serial correlation of 0.51 indicates that about 51.0% of current Cognition Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Cognition Therapeutics lagged returns against current returns
Autocorrelation, which is Cognition Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cognition Therapeutics' stock expected returns. We can calculate the autocorrelation of Cognition Therapeutics returns to help us make a trade decision. For example, suppose you find that Cognition Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cognition Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cognition Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cognition Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cognition Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Cognition Therapeutics Lagged Returns
When evaluating Cognition Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cognition Therapeutics stock have on its future price. Cognition Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cognition Therapeutics autocorrelation shows the relationship between Cognition Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Cognition Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.